ReviewCurrent rheumatology reports2011
Review of clinical registries of psoriatic arthritis: lessons learned?: value for the future?
Review in Current rheumatology reports, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 15 citations in OpenAlex.
- Evaluating the cost-effectiveness of biologic treatments for psoriatic arthritis: can we make better use of patient data registries?Clinical rheumatology · 2017Article
- Article
- Review
- Prevalence and treatment patterns of psoriatic arthritis in the UK.Rheumatology (Oxford, England) · 2013Article
- How can psoriatic arthritis be diagnosed early?Current rheumatology reports · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
Psoriatic arthritis (PsA), an inflammatory musculoskeletal disease associated with psoriasis, is a complex disease in terms of its clinical presentation, etiology, and pathogenesis. Musculoskeletal presentations include peripheral arthritis, spondylitis, enthesitis, and dactylitis. To learn about the course of and prognosis for such a complex disease, it is important to observe patients longitudinally so that all aspects of the disease are recognized. Several registries have been developed to evaluate the course of and prognosis for patients with PsA. Based on such registries, it has been shown that PsA is more severe than previously thought, and that progression of joint damage is related to joint inflammation. Such registries also have been used to determine genetic factors in PsA and to identify biomarkers for both susceptibility and expression of the disease. Drug registries also have been developed to document response to new therapies as well as the long-term adverse effects resulting from such therapies. It is hoped that an international effort currently on the way will further enhance the contribution of PsA patient registries to address the etiology, pathogenesis, and outcome of this complex disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.